Thrilled to be kicking off this new venture!
Our APA-01 asset is an exceptional small molecule, but it has become apparent to us in the past year that PharmAla is simply too small to execute a full preclinical research program on its own.
With the formation of Restora Neuroscience, we’re thrilled to have an excellent technology partner that can help bring this molecule to IND next year.
CEO Nick Kadysh of @PharmAlaBiotech $MDMA speaks on a historic executive order to fast-track MDMA and psilocybin therapy for veterans https://t.co/4J9UcMiD7c
Will Avery, PharmAla Biotech CFO, highlights key financial milestones: FY24 revenue up 95% to $1 M+; resumed SAP shipments in Canada & the U.S.; expanded clinical trial deliveries via a new U.S. distributor; and raised $1.5 M+ through Q3 ’25.
$mdma #psychedelicnews
PharmAla delivers 500+ LaNeo™ 40mg MDMA capsules to Merhavim Mental Health Centre for a PTSD clinical trial.
In return for our MDMA, we gain access to the trial’s data & IP — a novel data-for-drug model that could reshape psychedelic research. 👏
👉 https://t.co/DITgRAGrl6
#psychedelics $mdma #mentalhealth
Blessed to be a part of the @PharmAlaBiotech team.
In the last six months, we have announced clients like Harvard, Yale, Mt.Sinai and many more.
Revenue is up 95% vs last year.
And now, Matthew Azrieli joins the team.
Big moves. Big players. Now back to work.
Don't miss your chance to hear directly from PharmAla's leadership! 🎤 CEO Nicholas Kadysh & CFO Will Avery present our Q1 results & company updates this Thursday at 4:30 PM EST.
Register now & submit your questions by noon tomorrow!
➡️ https://t.co/KvYWoCHfNC
$mdma #webinar #psychedelics